Physician profile
Mark D Sander
NPI 1508893314
$2,789.96
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,379 · 2020: $197 · 2021: $57.72 · 2022: $190 · 2023: $608 · 2024: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $965.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $642.57 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $227.80 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $209.78 | 2019-2020 | |
| Pfizer INC. | $207.93 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $203.13 | 2019 | |
| Allergan, INC. | $154.22 | 2019-2020 | |
| Lilly USA, LLC | $143.92 | 2019-2024 | Mounjaro, Zepbound |
| Amgen INC. | $131.03 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $117.36 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.67 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $72.72 | 2019 | |
| Glaxosmithkline, LLC. | $57.51 | 2019-2024 | Arexvy, Shingrix, Bexsero |
| Amarin Pharma, INC. | $57.13 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.49 | 2019-2024 | Xifaxan |
| Astellas Pharma US INC | $54.39 | 2020-2023 | Myrbetriq, Veozah |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $52.02 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Genentech USA, INC. | $43.22 | 2019 | |
| Novartis Pharmaceuticals Corporation | $41.17 | 2019-2023 | |
| Axsome Therapeutics, INC. | $32.74 | 2023 | Auvelity |
| Avanir Pharmaceuticals, INC. | $29.92 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $26.45 | 2019-2023 | Proquad, Gardasil 9, Vaqta |
| Idorsia Pharmaceuticals US INC | $16.59 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.75 | 2023 | Airduo Digihaler |
| Ultragenyx Pharmaceutical INC. | $14.66 | 2019 | |
| Shire North American Group INC | $14.59 | 2019 | |
| Sumitomo Pharma America, INC. | $13.79 | 2024 | Gemtesa |
| Boston Scientific Corporation | $13.60 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.14 | 2019 | |
| Currax Pharmaceuticals LLC | $11.86 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.58 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.